Burning Rock Biotech and Myriad Genetics agreed to expand global access to homologous recombination deficiency testing. Burning Rock will add the prostate Genomic Instability Score (prGIS) algorithm to its myChoice HRD Plus assay and develop new HRD tests on its OncoScreen Plus platform. The partnership matters for commercial rollout in oncology testing, because prGIS extends HRD analytics into prostate cancer contexts while OncoScreen Plus positions the provider to broaden test offerings across additional tumor types. The update also signals continued momentum in biomarker platforms where algorithm integration and platform development can materially change the addressable clinical and reimbursement landscape.